AC
ASND icon

Ascend Capital’s Ascendis Pharma A/S ASND Stock Holding History

Ascend Capital’s Portfolio ASND Stock Details ASND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-124,618
Closed -$4.99M – 209
2017
Q4 		$4.99M Buy
+124,618
New +$4.53M 0.19% 119

Other funds holding ASND

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Ascend Capital's ASND Position: Q1 2018 in Review

Ascend Capital sold out of Ascendis Pharma A/S (ASND) in Q1 2018, closing a stake of 124,618 shares — an estimated $4.99M sold.

Ascend Capital first reported a position in ASND in Q4 2017 and held it in 1 quarter. The position peaked at $4.99M in Q4 2017. 92 funds tracked by Wall St. Rank hold ASND as of Q1 2018.

  • Ascend Capital reported no remaining Ascendis Pharma A/S position as of Q1 2018 after selling out during the quarter.
  • Ascend Capital sold 124,618 Ascendis Pharma A/S shares in Q1 2018, an estimated $4.99M.
  • Ascend Capital first reported a position in Ascendis Pharma A/S in Q4 2017 and held it in 1 quarter.
  • Ascend Capital's Ascendis Pharma A/S position peaked at $4.99M in Q4 2017.
  • 92 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2018.

Based on Ascend Capital's 13F filing for Q1 2018, filed 14 May 2018.